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Abstract 
Indirect evidence supports altered glutamate signaling with Alzheimer’s disease, however, it is not known 
if glutamate neurotransmission is impacted prior to cognitive decline.  We examined cognition and 
glutamate neurotransmission in 2-4 month AβPP/PS1, an Alzheimer’s disease model, and age-matched 
control mice.  There were no differences in learning and memory as assessed by Morris water maze.  
However, in vivo electrochemical measures of potassium-evoked glutamate release in the CA1, but not 
the CA3 or dentate, was significantly elevated in AβPP/PS1 mice.  These data support changes in the 
glutamatergic system that precedes cognitive decline in a mouse model of Alzheimer’s disease.   
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Introduction 
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder resulting in severe impairment in 
new learning and memory, and eventually progressive dementia. In the United States, AD is the 6th 
leading cause of death and over 5.2 million Americans have the disease [1]. There has not been a new 
FDA approved drug to treat AD since 2003, therefore, it is imperative that we find a novel therapeutic 
target or opportune treatment window that exists prior to cognitive decline with the potential to slow or 
stop AD progression. Increasing evidence supports the glutamatergic system as a possible early biomarker 
that meets these criteria [2–11].  
Glutamate (Glu) is the major excitatory neurotransmitter in the mammalian CNS and several studies have 
implicated its involvement in AD pathologies including soluble Aβ42, deposition of Aβ in plaques, and 
hyperphosphorylated tau protein in tangles [6,12–28].  Recent evidence from AβPP/PS1 mice, a model of 
AD, and post mortem human central nervous system tissue suggest that altered extracellular Glu levels 
and function change as AD progresses.  For example, vesicular Glu transporter 1 boutons are elevated in 
pre-clinical AD cases (possibly through interaction with soluble Aβ) but are significantly reduced and 
associated with Aβ plaque accumulation in end-stage AD cases and AβPP/PS1 mice [12].    Given these 
findings, we believe that altered Glu neurotransmission may be instrumental not only in presenting 
symptoms, such as memory loss, but that extracellular Glu levels may also be a useful early biomarker 
and early therapeutic target of AD.  
AβPP/PS1 mice, an established model of AD, are cognitively normal and lack AD neuropathology at 2-4 
months of age, but begin showing cognitive decline and amyloid plaque accumulation at approximately 6-
8 months of age [18,29–36].  In the present studies, we examined cognition (Morris water maze; MWM) 
and Glu neurotransmission (in vivo electrochemistry) in the CA1, CA3 and DG regions of the 
hippocampus in 2-4 month anesthetized AβPP/PS1 mice.  
Materials and Methods 
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1. Animals 
AβPP/PS1 mice are double transgenic mice expressing a chimeric mouse/human amyloid precursor 
protein (Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1-dE9).  Both mutations were directed 
to CNS neurons and have been associated with early-onset AD. Two to four month old group housed, 
male AβPP/PS1 (B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J; 034832) and C57BL/6J (000664) mice were 
obtained from Jackson Laboratory (Bar Harbor, ME) and used for all experiments.  Protocols for animal 
use were approved by the Laboratory Animal Care and Use Committee at Southern Illinois University 
School of Medicine.  Animals were housed according to approved guidelines, on a 12:12 hour light: dark 
cycle, and food and water were available ad libitum.   
2. Morris Water Maze 
MWM consisted of five consecutive learning days where mice were placed in a large tank of opaque 
water at various starting positions.  The mice were trained to navigate to a platform at a fixed point 
based on visual cues, and remain there for 10 seconds.  Mice underwent three swimming trials on each 
of the five training days, with a minimum of 20 minutes between trials.  Mice had two rest days prior to 
undergoing a single probe trial.  During the probe, mice were placed in the tank of water for 60 seconds, 
without the platform.  Data parameters were recorded using video tracking software with the ANY-maze 
system (Stoelting Co., Wood Dale, IL, USA).   
3. Glutamate Recordings 
Enzyme-based microelectrode arrays (MEA) with platinum recording sites were obtained from CenMeT 
(Lexington, KY).  Twenty MEAs were used for this study with an average Glu sensitivity of 11.7 
pA/µM (R2 = 0.996), selectivity ratio over ascorbic acid of 386:1, and a signal-to-noise ratio of 0.5 µM. 
A single barrel glass micropipette was attached to the MEA assembly to  locally apply isotonic KCl (pH 
7.4) [37,38].  Mice were anesthetized with isoflurane and the MEA assemblies were lowered into the 
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CA1 (AP: -2.0, ML: ±1.0, DV: -1.7 mm), DG (AP: -2.0, ML: ±1.0, DV: -2.2 mm, or CA3 (AP: -2.0, 
ML: ±2.0, DV: -2.2 mm) based on coordinates from Paxinos and Franklin [39].  Solutions were pressure 
ejected from the micropipette using a Picospritzer (Parker Hannafin, Morton, IL) and volumes were 
monitored using a stereomicroscope fitted with a reticule.  A constant volume of 70 mM KCl (~100-200 
nL) was used to elicit Glu release to allow for direct comparisons between the groups.  Amperometric 
data, time, and pressure ejection marks were recorded and analyzed using a FASTmkIII system and 
FAST Analysis Version 5.2 software (Quanteon, LLC, Nicholasville, KY, USA).        
4. Data Analysis 
Data from MWM training days was analyzed using a two-way ANOVA followed by a Fisher’s LSD 
post-hoc test and probe data was analyzed using an unpaired Student’s t-test.  Glu data was analyzed 
using a one-way ANOVA followed by a Fisher’s LSD post-hoc test.  Correlations between MWM and 
Glu data were established using Pearson’s correlation. Data was reported as Mean ± SEM and 
significance was defined as p<0.05.  Seven to ten mice were used per group. 
Results  
1. Morris Water Maze 
All mice underwent cognitive testing using the MWM prior to in vivo Glu measures.  Parameters 
analyzed for the initial five training days included duration, distance, average speed, path efficiency, and 
time spent in target quadrant.  Parameters analyzed for the single probe trial included those previously 
mentioned and the number of platform entries, time spent in annulus 40, latency, distance and path 
efficiency to first platform entry.  During the single day probe session, AβPP/PS1 mice (0.261 ± 0.005 
m/s) swam significantly (p<0.05) faster compared to C57BL/6J mice (0.240 ± 0.009 m/s).  To account for 
differences in swimming speed, we normalized probe data to total distance swam (in meters) for each 
mouse.  We did not observe differences between genotypes during training or probe in any of the 
parameters measured (data not shown) as reported elsewhere [35].   
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2. Glutamate Measures 
Basal Glu levels were similar in all hippocampal subregions (~1.0 µM; data not shown).    We observed 
significantly more KCl-evoked Glu release in the CA1 of AβPP/PS1 mice compared to age-matched 
controls (9.1 ± 1.5 µM vs. 2.9 ± 0.3 µM, respectively; p<0.001), however, no differences were observed 
in the DG or CA3 (Figure 1a&b).  Glu clearance  (time from peak amplitude back to basal levels) from 
the extracellular space was similar in the CA1 of the AβPP/PS1 mice compared to controls (representative 
traces, Figure 1a).  However, there was an approximate three-fold increase in Glu uptake rate in the CA1 
of AβPP/PS1 mice compared to controls (3.4 ± 0.5 µM/sec vs. 0.9 ± 0.1 µM/sec, respectively; p<0.05), 
which accounts for similar clearance times (Figure 1c). Additionally, we observed a strong negative 
correlation (r= -0.621) between KCl-evoked Glu release in the CA1 and the number of platform entries 
per meter swam during the probe trial in the AβPP/PS1 mice (Figure 2, solid line; p=0.10), while no 
correlation (r= -0.036) was observed in the C57BL/6J control mice (Figure 2; dashed line; p=0.93).   
Discussion 
Similar to previous reports, we did not observe learning and/or memory differences in 2-4 month old 
AβPP/PS1 mice compared to age-matched controls, supporting that AβPP/PS1 mice in this age range 
remain cognitively intact [32].  While basal Glu levels were similar in all hippocampal subregions, we did 
observe increased potassium-evoked Glu release in 2-4 month AβPP/PS1 mice.    Consistent with our 
basal Glu findings, researchers using magnetic resonance spectroscopy (MRS) in 2-4 month AβPP/PS1 
mice have shown no differences in hippocampal Glu metabolite levels compared to age-matched controls 
[40,41].  However, stimulus evoked release was not examined in these MRS studies nor is MRS specific 
enough to elucidate the subregional hippocampal differences observed in the present study.  Only changes 
in CA1 evoked-Glu release were observed, which corresponds to the neuropathological progression of 
AD.  Magnetic resonance imaging studies have shown that hippocampal atrophy begins in the CA1 
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subfield of mild cognitively impaired patients and then affects other subregions as the diseases progresses 
to AD [42], a finding consistent with the Braak stages of AD [43].  
Interestingly, there was no difference in the time it took to clear Glu from the extracellular space in the 
CA1 despite evoked Glu release being approximately three times greater in the AβPP/PS1.  This was 
likely due to an approximate three-fold increase in uptake rate in the CA1 of AβPP/PS1 mice, which may 
indicate that the numbers of glial Glu transporters are increased as a compensatory mechanism to prevent 
excitotoxicity. 
The increased KCl-evoked Glu release in the CA1 negatively correlated with performance on the memory 
portion of the MWM task.  This correlation supports a specific threshold of Glu release in AβPP/PS1 
mice that negatively impacts memory formation or information recall, possibly due to overactivation of 
N-methyl-D-aspartate (NMDA) receptors that causes impairments in new learning and memory before the 
onset of excitotoxicity [44]. 
Taken together, these data support that altered Glu neurotransmission precedes neuropathology and 
cognitive decline in AβPP/PS1 mice and may be a potential early biomarker for AD.   Future studies will 
evaluate Glu levels and kinetics during and after cognitive decline in AβPP/PS1 mice to understand how 
Glu neurotransmission changes during AD progression as well as exploring potential therapeutic 
treatments.  
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Figure Legends: 
Figure 1: KCl-evoked Glu release and uptake in the hippocampus.  a) Representative traces taken 
from the CA1 of AβPP/PS1 mice (black line) and C57BL/6J mice (gray line).  Arrows indicate local 
application of 70 mM KCl (150-200 nl).  b & c)  KCl-evoked Glu release and uptake, respectively, was 
significantly elevated in the CA1 region of the hippocampus of AβPP/PS1 mice compared to C57BL/6J 
mice, but not in the DG or CA3.    Seven to ten mice were used per group.  *p<0.05; ***p<0.001 based 
on a one-way ANOVA with a Fisher’s LSD post-hoc. 
Figure 2: KCl-evoked Glu release in the CA1 vs. number of platform entries per meter swam.  
Correlation of KCl-evoked Glu release in the CA1 (Figure 1b) with the number of platform entries per 
meter swam during the probe session of MWM.  Pearson’s correlation when evaluating AβPP/PS1 mice  
was r = -0.621 (p=0.10; solid line).  Pearson’s correlation when evaluating C57BL/6J mice was r = -0.036 
p=0.93; dashed line).   
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